Novel Pathogenetic Mechanisms in Myocarditis: Nitric Oxide Signaling

Heart Failure Clinics

Volumn 1, Issue 3, 2005, Pages 345-361

  Kittleson, Michelle M ^a   Lowenstein, Charles J ^a   Hare, Joshua M ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL L TYPE; CREATINE KINASE; NITRIC OXIDE;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; BETA ADRENERGIC RECEPTOR BLOCKING; CALCIUM TRANSPORT; CELL COMPARTMENTALIZATION; CHAGAS DISEASE; CYTOTOXIC T LYMPHOCYTE; HEART FAILURE; HEART MITOCHONDRION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE OXYGEN CONSUMPTION; HUMAN; INNATE IMMUNITY; INOTROPISM; MITOCHONDRIAL RESPIRATION; NITROSYLATION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; REVIEW; VIRUS INDUCTION; VIRUS MYOCARDITIS; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS VIRULENCE;

ANIMALS; APOPTOSIS; CELL RESPIRATION; CHAGAS DISEASE; HEART FAILURE; HEART FAILURE, CONGESTIVE; HUMANS; IMMUNITY, INNATE; IMMUNITY, NATURAL; MITOCHONDRIA, HEART; MYOCARDIAL CONTRACTION; MYOCARDITIS; NITRIC OXIDE; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 33646002966     PISSN: 15517136     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hfc.2005.06.002     Document Type: Review

References (182)

1. Barouch L.A., Harrison R.W., Skaf M.W., et al. Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms. Nature 416 (2002) 337-339
2. Khan S.A., Skaf M.W., Harrison R.W., et al. Nitric oxide regulation of myocardial contractility and calcium cycling: independent impact of neuronal and endothelial nitric oxide synthases. Circ Res 92 (2003) 1322-1329
3. Matsumoto A., Comatas K.E., Liu L., et al. Screening for nitric oxide-dependent protein-protein interactions. Science 301 (2003) 657-661
4. Hess D.T., Matsumoto A., Kim S.O., et al. Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol 6 (2005) 150-166
5. Michel T., and Feron O. Nitric oxide synthases: which, where, how, and why?. J Clin Invest 100 (1997) 2146-2152
6. Wink D.A., and Mitchell J.B. Chemical biology of nitric oxide: insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic Biol Med 25 (1998) 434-456
7. Hare J.M. Nitric oxide and excitation-contraction coupling. J Mol Cell Cardiol 35 (2003) 719-729
8. Simon D.I., Mullins M.E., Jia L., et al. Polynitrosylated proteins: characterization, bioactivity, and functional consequences. Proc Natl Acad Sci USA 93 (1996) 4736-4741
9. Scharfstein J.S., Keaney Jr. J.F., Slivka A., et al. In vivo transfer of nitric oxide between a plasma protein-bound reservoir and low molecular weight thiols. J Clin Invest 94 (1994) 1432-1439
10. Wink D.A., Cook J.A., Kim S.Y., et al. Superoxide modulates the oxidation and nitrosation of thiols by nitric oxide-derived reactive intermediates. Chemical aspects involved in the balance between oxidative and nitrosative stress. J Biol Chem 272 (1997) 11147-11151
11. Stamler J.S., Jaraki O., Osborne J., et al. Nitric oxide circulates in mammalian plasma rimarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci USA 89 (1992) 7674-7677
12. Stamler J.S., Lamas S., and Fang F.C. Nitrosylation: the prototypic redox-based signaling mechanism. Cell 106 (2001) 675-683
13. Gow A.J., Buerk D.G., and Ischiropoulos H. A novel reaction mechanism for the formation of S-nitrosothiol in vivo. J Biol Chem 272 (1997) 2841-2845
14. Layland J., Li J.M., and Shah A.M. Role of cyclic GMP-dependent protein kinase in the contractile response to exogenous nitric oxide in rat cardiac myocytes. J Physiol (Lond) 540 (2002) 457-467
15. Senzaki H., Carolyn J., Juang G.J., et al. Cardiac phosphodiesterase 5 (cGMP-specific) modulates {beta}-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J 15 (2001) 1718-1726
16. Gow A.J., Chen Q., Hess D.T., et al. Basal and stimulated protein S-nitrosylation in multiple cell types and tissues. J Biol Chem 277 (2002) 9637-9640
17. Sun J., Xin C., Eu J.P., et al. Cysteine-3635 is responsible for skeletal muscle ryanodine receptor modulation by NO. Proc Natl Acad Sci USA 98 (2001) 11158-11162
18. Paolocci N., Ekelund U.E.G., Isoda T., et al. cGMP-independent inotropic effects of nitric oxide and peroxynitrite donors: potential role for nitrosylation. Am J Physiol Heart Circ Physiol 279 (2000) H1982-H1988
19. Feron O., Smith T.W., Michel T., et al. Dynamic targeting of the agonist-stimulated m2 muscarinic acetylcholine Rreceptor to caveolae in cardiac myocytes. J Biol Chem 272 (1997) 17744-17748
20. Feron O., Saldana F., Michel J.B., et al. The endothelial nitric-oxide synthase-caveolin regulatory cycle. J Biol Chem 273 (1998) 3125-3128
21. Hare J.M., Lofthouse R.A., Juang G.J., et al. Contribution of caveolin protein abundance to augmented nitric oxide signaling in conscious dogs with pacing-induced heart failure. Circ Res 86 (2000) 1085-1092
22. Fulton D., Gratton J.P., McCabe T.J., et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399 (1999) 597-601
23. Dimmeler S., Fleming I., Fisslthaler B., et al. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature 399 (1999) 601-605
24. George W.J., Polson J.B., O'Toole A.G., et al. Elevation of guanosine 3′,5′-cyclic phosphate in rat heart after perfusion with acetylcholine. Proc Natl Acad Sci USA 66 (1970) 398-403
25. George W.J., Wilkerson R.D., and Kadowitz P.J. Influence of acetylcholine on contractile force and cyclic nucleotide levels in the isolated perfused rat heart. J Pharmacol Exp Ther 184 (1973) 228-235
26. Shah A.M., Lewis M.J., and Henderson A.H. Effects of 8-bromo-cyclic GMP on contraction and on inotropic response of ferret cardiac muscle. J Mol Cell Cardiol 23 (1991) 55-64
27. Krause E.G., Halle W., and Wollenberger A. Effect of dibutyryl cyclic GMP on cultured beating rat heart cells. Adv Cyclic Nucleotide Res 1 (1972) 301-305
28. Shah A.M., Spurgeon H.A., Sollott S.J., et al. 8-bromo-cGMP reduces the myofilament response to Ca2+ in intact cardiac myocytes. Circ Res 74 (1994) 970-978
29. Xie Y.W., Shen W., Zhao G., et al. Role of endothelium-derived nitric oxide in the modulation of canine myocardial mitochondrial respiration in vitro: implications for the development of heart failure. Circ Res 79 (1996) 381-387
30. Takimoto E., Champion H.C., Li M., et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11 (2005) 214-222
31. Henning R.J., Khalil I.R., and Levy M.N. Vagal stimulation attenuates sympathetic enhancement of left ventricular function. Am J Physiol 258 (1990) H1470-H1475
32. Watanabe A.M., and Besch Jr. H.R. Interaction between cyclic adenosine monophosphate and cyclic gunaosine monophosphate in guinea pig ventricular myocardium. Circ Res 37 (1975) 309-317
33. Kanai A.J., Mesaros S., Finkel M.S., et al. Beta -adrenergic regulation of constitutive nitric oxide synthase in cardiac myocytes. Am J Physiol Cell Physiol 273 (1997) C1371-C1377
34. Gauthier C., Leblais V., Kobzik L., et al. The negative inotropic dffect of beta 3-adrenoceptor stimulation is mediated by activation of a nitric oixide synthase pathway in human ventricle. J Clin Invest 102 (1998) 1377-1384
35. Varghese P., Harrison R.W., Lofthouse R.A., et al. {beta}3-adrenoceptor deficiency blocks nitric oxide-dependent inhibition of myocardial contractility. J Clin Invest 106 (2000) 697-703
36. Hartzell H.C., and Fischmeister R. Opposite effects of cyclic GMP and cyclic AMP on Ca2 + current in single heart cells. Nature 323 (1986) 273-275
37. Mery P., Lohmann S.M., Walter U., et al. Ca2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. Proc Natl Acad Sci USA 88 (1991) 1197-1201
38. Mery P.F., Pavoine C., Belhassen L., et al. Nitric oxide regulates cardiac Ca2+ current. Involvement of cGMP- inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation. J Biol Chem 268 (1993) 26286-26295
39. Han X., Kubota I., Feron O., et al. Muscarinic cholinergic regulation of cardiac myocyte ICa-L is absent in mice with targeted disruption of endothelial nitric oxide synthase. Proc Natl Acad Sci USA 95 (1998) 6510-6515
40. Feron O., Dessy C., Opel D.J., et al. Modulation of the endothelial nitric-oxide synthase-caveolin interaction in cardiac myocytes. Implications for the autonomic regulation of heart rate. J Biol Chem 273 (1998) 30249-30254
41. Han X., Shimoni Y., and Giles W.R. A cellular mechanism for nitric oxide-mediated cholinergic control of mammalian heart rate. J Gen Physiol 106 (1995) 45-65
42. Han X., Shimoni Y., and Giles W.R. An obligatory role for nitric oxide in autonomic control of mammalian heart rate. J Physiol 476 (1994) 309-314
43. Levi R.C., Alloatti G., Penna C., et al. Guanylate-cyclase-mediated inhibition of cardiac ICa by carbachol and sodium nitroprusside. Pflugers Arch 426 (1994) 419-426
44. Forman H.J., Fukuto J.M., and Torres M. Redox signaling: thiol chemistry defines which reactive oxygen and nitrogen species can act as second messengers. Am J Physiol Cell Physiol 287 (2004) C246-C256
45. Foster M.W., McMahon T.J., and Stamler J.S. S-nitrosylation in health and disease. Trends Mol Med 9 (2003) 160-168
46. Xu K.Y., Huso D.L., Dawson T.M., et al. Nitric oxide synthase in cardiac sarcoplasmic reticulum. Proc Natl Acad Sci USA 96 (1999) 657-662
47. Sears C.E., Bryant S.M., Ashley E.A., et al. Cardiac neuronal nitric oxide synthase isoform regulates myocardial contraction and calcium handling. Circ Res 92 5 (2003) e52-e59
48. Hess D.T., Matsumoto A., Kim S.O., et al. Protein S-nitrosylation: purview and parameters. Nat Rev Mol Cell Biol 6 2 (2005) 150-166
49. Liu L., Yan Y., Zeng M., et al. Essential roles of S-nitrosothiols in vascular homeostasis and endotoxic shock. Cell 116 (2004) 617-628
50. Liu L., Hausladen A., Zeng M., et al. A metabolic enzyme for S-nitrosothiol conserved from bacteria to humans. Nature 410 (2001) 490-494
51. Xu L., Eu J.P., Meissner G., et al. Activation of the cardiac calcium release channel (ryanodine receptor) by poly-S-nitrosylation. Science 279 (1998) 234-237
52. Eu J.P., Sun J., Xu L., et al. The skeletal muscle calcium release channel: coupled O2 sensor and NO signaling functions. Cell 102 (2000) 499-509
53. Campbell D.L., Stamler J.S., and Strauss H.C. Redox modulation of L-type calcium channels in ferret ventricular myocytes. Dual mechanism regulation by nitric oxide and S-nitrosothiols. J Gen Physiol 108 (1996) 277-293
54. Kojda G., Kottenberg K., Nix P., et al. Low increase in cGMP induced by organic nitrates and nitrovasodilators improves contractile response of rat ventricular myocytes. Circ Res 78 (1996) 91-101
55. Mohan P., Brutsaert D.L., Paulus W.J., et al. Myocardial contractile response to nitric oxide and cGMP. Circulation 93 (1996) 1223-1229
56. Preckel B., Kojda G., Schlack W., et al. Inotropic effects of glyceryl trinitrate and spontaneous NO donors in the dog heart. Circulation 96 (1997) 2675-2682
57. Wawrzynow A., and Collins J.H. Chemical modification of the Ca(2 +)-ATPase of rabbit skeletal muscle sarcoplasmic reticulum: identification of sites labeled with aryl isothiocyanates and thiol-directed conformational probes. Biochim Biophys Acta 1203 (1993) 60-70
58. Eley D.W., Eley J.M., Korecky B., et al. Impairment of cardiac contractility and sarcoplasmic reticulum Ca2+ ATPase activity by hypochlorous acid: reversal by dithiothreitol. Can J Physiol Pharmacol 69 (1991) 1677-1685
59. Stamler J.S., and Hausladen A. Oxidative modifications in nitrosative stress. Nat Struct Biol 5 (1998) 247-249
60. Khan S.A., Lee K., Minhas K.M., et al. Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling. Proc Natl Acad Sci USA 101 (2004) 15944-15948
61. Cappola T.P., Cope L., Cernetich A., et al. Deficiency of different nitric oxide synthase isoforms activates divergent transcriptional programs in cardiac hypertrophy. Physiol Genomics 14 (2003) 25-34
62. Barouch L.A., Cappola T.P., Harrison R.W., et al. Combined loss of neuronal and endothelial nitric oxide synthase causes premature mortality and age-related hypertrophic cardiac remodeling in mice. J Mol Cell Cardiol 35 (2003) 637-644
63. Balligand J.L., Kobzik L., Han X., et al. Nitric oxide-dependent parasympathetic signaling is due to activation of constitutive endothelial (type III) nitric oxide synthase in cardiac myocytes. J Biol Chem 270 (1995) 14582-14586
64. Gyurko R., Kuhlencordt P., Fishman M.C., et al. Modulation of mouse cardiac function in vivo by eNOS and ANP. Am J Physiol Heart Circ Physiol 278 (2000) H971-H981
65. Shen W., Hintze T.H., and Wolin M.S. Nitric oxide: an important signaling mechanism between vascular endothelium and parenchymal cells in the regulation of oxygen consumption. Circulation 92 (1995) 3505-3512
66. Shen W., Wolin M.S., and Hintze T.H. Defective endogenous nitric oxide-mediated modulation of cellular respiration in canine skeletal muscle after the development of heart failure. J Heart Lung Transplant 16 (1997) 1026-1034
67. Gross W.L., Bak M.I., Ingwall J.S., et al. Nitric oxide inhibits creatine kinase and regulates rat heart contractile reserve. Proc Natl Acad Sci USA 93 (1996) 5604-5609
68. Bates T.E., Loesch A., Burnstock G., et al. Mitochondrial nitric oxide synthase: a ubiquitous regulator of oxidative phosphorylation?. Biochem Biophys Res Commun 218 (1996) 40-44
69. Kanai A.J., Pearce L.L., Clemens P.R., et al. Identification of a neuronal nitric oxide synthase in isolated cardiac mitochondria using electrochemical detection. Proc Natl Acad Sci USA 98 (2001) 14126-14131
70. Shen W., Xu X., Ochoa M., et al. Role of nitric oxide in the regulation of oxygen consumption in conscious dogs. Circ Res 75 (1994) 1086-1095
71. Suto N., Mikuniya A., Okubo T., et al. Nitric oxide modulates cardiac contractility and oxygen consumption without changing contractile efficiency. Am J Physiol Heart Circ Physiol 275 (1998) H41-H49
72. Recchia F.A., McConnell P.I., Bernstein R.D., et al. Reduced nitric oxide production and altered myocardial metabolism during the decompensation of pacing-induced heart failure in the conscious D\dog. Circ Res 83 (1998) 969-979
73. Tada H., Thompson C.I., Recchia F.A., et al. Myocardial glucose uptake is regulated by nitric oxide via endothelial nitric oxide synthase in Langendorff mouse heart. Circ Res 86 (2000) 270-274
74. Saavedra W.F., Paolocci N., St.John M.E., et al. Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ Res 90 (2002) 297-304
75. Espey M.G., Miranda K.M., Pluta R.M., et al. Nitrosative capacity of macrophages is dependent on nitric-oxide synthase induction signals. J Biol Chem 275 (2000) 11341-11347
76. Oyama J., Shimokawa H., Momii H., et al. Role of nitric oxide and peroxynitrite in the cytokine-induced sustained myocardial dysfunction in dogs in vivo. J Clin Invest 101 (1998) 2207-2214
77. Ferdinandy P., Danial H., Ambrus I., et al. Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res 87 (2000) 241-247
78. Ekelund U.E.G., Harrison R.W., Shokek O., et al. Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res 85 (1999) 437-445
79. Chiamvimonvat N., O'Rourke B., Kamp T.J., et al. Functional consequences of sulfhydryl modification in the pore-forming subunits of cardiovascular Ca2+ and Na+ channels. Circ Res 76 (1995) 325-334
80. Thomas J.A., Poland B., and Honzatko R. Protein sulfhydryls and their role in the antioxidant function of protein S-thiolation. Arch Biochem Biophys 319 (1995) 1-9
81. Takasago T., Goto Y., Kawaguchi O., et al. Ryanodine wastes oxygen consumption for Ca2 + handling in the dog heart. A new pathological heart model. J Clin Invest 92 (1993) 823-830
82. Vatner D.E., Sato N., Kiuchi K., et al. Decrease in myocardial ryanodine receptors and altered excitation-contraction coupling early in the development of heart failure. Circulation 90 (1994) 1423-1430
83. Shannon T.R., Ginsburg K.S., and Bers D.M. Quantitative assessment of the SR Ca2+ leak-load relationship. Circ Res 91 (2002) 594-600
84. Kawakami M., and Okabe E. Superoxide anion radical-triggered Ca2+ release from cardiac sarcoplasmic reticulum through ryanodine receptor Ca2 + channel. Mol Pharmacol 53 (1998) 497-503
85. Hare J.M., and Stamler J.S. NO/Redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest 115 3 (2005) 509-517
86. Wink D.A., Miranda K.M., Espey M.G., et al. Mechanisms of the antioxidant effects of nitric oxide. Antioxid Redox Signal 3 (2001) 203-213
87. Rubbo H., Radi R., Trujillo M., et al. Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. Formation of novel nitrogen-containing oxidized lipid derivatives. J Biol Chem 269 (1994) 26066-26075
88. Yasmin W., Strynadka K.D., and Schulz R. Generation of peroxynitrite contributes to ischemia-reperfusion injury in isolated rat hearts. Cardiovasc Res 33 (1997) 422-432
89. Hare J.M., Loh E., Creager M.A., et al. Nitric oxide inhibits the positive inotropic response to beta-adrenergic stimulation in humans with left ventricular dysfunction. Circulation 92 (1995) 2198-2203
90. Hare J.M., Givertz M.M., Creager M.A., et al. Increased sensitivity to nitric oxide synthase inhibition in patients with heart failure: potentiation of beta-adrenergic inotropic responsiveness. Circulation 97 (1998) 161-166
91. Barry W.H. Mechanisms of immune-mediated myocyte injury. Circulation 89 (1994) 2421-2432
92. Yang X., Chowdhury N., Cai B., et al. Induction of myocardial nitric oxide synthase by cardiac allograft rejection. J Clin Invest 94 (1994) 714-721
93. Levine B., Kalman J., Mayer L., et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323 (1990) 236-241
94. Torre-Amione G., Kapadia S., Benedict C., et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 27 (1996) 1201-1206
95. Torre-Amione G., Kapadia S., Lee J., et al. Tumor necrosis factor-{alpha} and tumor necrosis factor receptors in the failing human heart. Circulation 93 (1996) 704-711
96. Nathan C. Inducible nitric oxide synthase: what difference does it make?. J Clin Invest 100 (1997) 2417-2423
97. Haywood G.A., Tsao P.S., der Leyen H.E., et al. Expression of inducible nitric oxide synthase in human heart failure. Circulation 93 (1996) 1087-1094
98. de Belder A.J., Radomski M.W., Why H.J., et al. Myocardial calcium-independent nitric oxide synthase activity is present in dilated cardiomyopathy, myocarditis, and postpartum cardiomyopathy but not in ischaemic or valvar heart disease. Br Heart J 74 (1995) 426-430
99. de Belder A.J., Radomski M.W., Why H.J., et al. Nitric oxide synthase activities in human myocardium. Lancet 341 (1993) 84-85
100. Habib F.M., Springall D.R., Davies G.J., et al. Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 347 (1996) 1151-1155
101. Thoenes M., Forstermann U., Tracey W.R., et al. Expression of inducible nitric oxide synthase in failing and non-failing human heart. J Mol Cell Cardiol 28 (1996) 165-169
102. Berry C.E., and Hare J.M. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol 555 (2004) 589-606
103. Damy T., Ratajczak P., Robidel E., et al. Up-regulation of cardiac nitric oxide synthase 1-derived nitric oxide after myocardial infarction in senescent rats. FASEB J 17 (2003) 1934-1936
104. Damy T., Ratajczak P., Shah A.M., et al. Increased neuronal nitric oxide synthase-derived NO production in the failing human heart. Lancet 363 (2004) 1365-1367
105. Bogdan C. Nitric oxide and the immune response. Nat Immunol 2 (2001) 907-916
106. Woodruff J.F. Viral myocarditis. A review. Am J Pathol 101 (1980) 425-484
107. Felker G.M., Boehmer J.P., Hruban R.H., et al. Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol 36 (2000) 227-232
108. McCarthy R.E., Boehmer J.P., Hruban R.H., et al. Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med 342 (2000) 690-695
109. Kirchhoff L.V. Chagas disease. In: Isselbacher K.J. (Ed). Harrison's principles of internal medicine (1994), McGraw-Hill, New York 176-177
110. Li B.Y., Qiao G.F., Zhou H., et al. Cytosolic-Ca2+ and coxsackievirus B3-induced apoptosis in cultured cardiomyocytes of rats. Zhongguo Yao Li Xue Bao 20 (1999) 395-399
111. Henke A., Launhardt H., Klement K., et al. Apoptosis in coxsackievirus B3-caused diseases: interaction between the capsid protein VP2 and the proapoptotic protein siva. J Virol 74 (2000) 4284-4290
112. Huber S.A., Budd R.C., Rossner K., et al. Apoptosis in coxsackievirus B3-induced myocarditis and dilated cardiomyopathy. Ann N Y Acad Sci 887 (1999) 181-190
113. Huber S.A. T cells expressing the [gamma][delta] T cell receptor induce apoptosis in cardiac myocytes. Cardiovasc Res 45 (2000) 579-587
114. Colston J.T., Chandrasekar B., and Freeman G.L. Expression of apoptosis-related proteins in experimental coxsackievirus myocarditis. Cardiovasc Res 38 (1998) 158-168
115. Badorff C., Lee G.H., Lamphear B.J., et al. Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy. Nat Med 5 (1999) 320-326
116. Wessely R., Klingel K., Santana L.F., et al. Transgenic expression of replication-restricted enteroviral genomes in heart muscle induces defective excitation-contraction coupling and dilated cardiomyopathy. J Clin Invest 102 (1998) 1444-1453
117. Binah O. Immune effector mechanisms in myocardial pathologies. Int J Mol Med 6 (2000) 3-16
118. Kawai C. From myocarditis to cardiomyopathy: mechanisms of inflammation and cell death: learning from the past for the future. Circulation 99 (1999) 1091-1100
119. Gebhard J.R., Perry C.M., Harkins S., et al. Coxsackievirus B3-induced myocarditis: perforin exacerbates disease, but plays no detectable role in virus clearance. Am J Pathol 153 (1998) 417-428
120. Felzen B., Shilkrut M., Less H., et al. Fas (CD95/Apo-1)-mediated damage to ventricular myocytes induced by cytotoxic T lymphocytes from perforin-deficient mice: a major role ror inositol 1,4,5-trisphosphate. Circ Res 82 (1998) 438-450
121. Seko Y., Shinkai Y., Kawasaki A., et al. Evidence of perforin-mediated cardiac myocyte injury in acute murine myocarditis caused by Coxsackie virus B3. J Pathol 170 (1993) 53-58
122. Seko Y., Shinkai Y., Kawasaki A., et al. Expression of perforin in infiltrating cells in murine hearts with acute myocarditis caused by coxsackievirus B3. Circulation 84 (1991) 788-795
123. Young L.H., Joag S.V., Zheng L.M., et al. Perforin-mediated myocardial damage in acute myocarditis. Lancet 336 (1990) 1019-1021
124. Guthrie M., Lodge P.A., and Huber S.A. Cardiac injury in myocarditis induced by Coxsackievirus group B, type 3 in Balb/c mice is mediated by Lyt 2 + cytolytic lymphocytes. Cell Immunol 88 (1984) 558-567
125. Penninger J.M., and Bachmaier K. Review of microbial infections and the immune response to cardiac antigens. J Infect Dis 181 Suppl 3 (2000) S498-S504
126. Rose N.R. Viral damage or 'molecular mimicry'-placing the blame in myocarditis. Nat Med 6 (2000) 631-632
127. Gauntt C.J., Arizpe H.M., Higdon A.L., et al. Molecular mimicry, anti-coxsackievirus B3 neutralizing monoclonal antibodies, and myocarditis. J Immunol 154 (1995) 2983-2995
128. Beisel K.W., Srinivasappa J., and Prabhakar B.S. Identification of a putative shared epitope between coxsackie virus B4 and alpha cardiac myosin heavy chain. Clin Exp Immunol 86 (1991) 49-55
129. Lanzavecchia A. How can cryptic epitopes trigger autoimmunity?. J Exp Med 181 (1995) 1945-1948
130. Frantz S., Kelly R.A., and Bourcier T. Role of TLR-2 in the activation of nuclear factor kappa B by oxidative stress in cardiac myocytes. J Biol Chem 276 (2001) 5197-5203
131. Frantz S., Kobzik L., Kim Y.D., et al. Toll4 (TLR4) expression in cardiac myocytes in normal and failing myocardium. J Clin Invest 104 (1999) 271-280
132. MacMicking J., Xie Q.W., and Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 15 (1997) 323-350
133. Hiraoka Y., Kishimoto C., Takada H., et al. Nitric oxide and murine coxsackievirus B3 myocarditis: aggravation of myocarditis by inhibition of nitric oxide synthase. J Am Coll Cardiol 28 (1996) 1610-1615
134. Lowenstein C.J., Hill S.L., Lafond-Walker A., et al. Nitric oxide inhibits viral replication in murine myocarditis. J Clin Invest 97 (1996) 1837-1843
135. Mikami S., Kawashima S., Kanazawa K., et al. Expression of nitric oxide synthase in a murine model of viral myocarditis induced by coxsackievirus B3. Biochem Biophys Res Commun 220 (1996) 983-989
136. Zaragoza C., Ocampo C., Saura M., et al. The role of inducible nitric oxide synthase in the host response to Coxsackievirus myocarditis. Proc Natl Acad Sci USA 95 (1998) 2469-2474
137. Cao W., Bao C., and Lowenstein C.J. Inducible nitric oxide synthase expression inhibition by adenovirus E1A. Proc Natl Acad Sci USA 100 (2003) 7773-7778
138. Padalko E., Ohnishi T., Matsushita K., et al. Peroxynitrite inhibition of coxsackievirus infection by prevention of viral RNA entry. Proc Natl Acad Sci USA 101 (2004) 11731-11736
139. Zaragoza C., Ocampo C.J., Saura M., et al. Nitric oxide inhibition of Coxsackievirus replication in vitro. J Clin Invest 100 (1997) 1760-1767
140. Saura M., Zaragoza C., McMillan A., et al. An antiviral mechanism of nitric oxide: inhibition of a viral protease. Immunity 10 (1999) 21-28
141. Zell R., Markgraf R., Schmidtke M., et al. Nitric oxide donors inhibit the coxsackievirus B3 proteinases 2A and 3C in vitro, virus production in cells, and signs of myocarditis in virus-infected mice. Med Microbiol Immunol (Berl) 193 (2004) 91-100
142. Badorff C., Fichtlscherer B., Muelsch A., et al. Selective delivery of nitric oxide to a cellular target: a pseudosubstrate-coupled dinitrosyl-iron complex inhibits the enteroviral protease 2A. Nitric Oxide 6 (2002) 305-312
143. Cao W., Baniecki M.L., McGrath W.J., et al. Nitric oxide inhibits the adenovirus proteinase in vitro and viral infectivity in vivo. FASEB J 17 (2003) 2345-2346
144. Badorff C., Berkely N., Mehrotra S., et al. Enteroviral protease 2A directly cleaves dystrophin and is inhibited by a dystrophin-based substrate analogue. J Biol Chem 275 (2000) 11191-11197
145. Badorff C., Fichtlscherer B., Rhoads R.E., et al. Nitric oxide inhibits dystrophin proteolysis by coxsackieviral protease 2A through S-nitrosylation: a protective mechanism against enteroviral cardiomyopathy. Circulation 102 (2000) 2276-2281
146. Petray P., Rottenberg M.E., Grinstein S., et al. Release of nitric oxide during the experimental infection with Trypanosoma cruzi. Parasite Immunol 16 (1994) 193-199
147. Pakianathan D.R., and Kuhn R.E. Trypanosoma cruzi affects nitric oxide production by murine peritoneal macrophages. J Parasitol 80 (1994) 432-437
148. Rottenberg M.E., Castanos-Velez E., de Mesquita R., et al. Intracellular co-localization of Trypanosoma cruzi and inducible nitric oxide synthase (iNOS): evidence for dual pathway of iNOS induction. Eur J Immunol 26 (1996) 3203-3213
149. Abrahamsohn I.A., and Coffman R.L. Trypanosoma cruzi: IL-10, TNF, IFN-gamma, and IL-12 regulate innate and acquired immunity to infection. Exp Parasitol 84 (1996) 231-244
150. Silva J.S., Vespa G.N., Cardoso M.A., et al. Tumor necrosis factor alpha mediates resistance to Trypanosoma cruzi infection in mice by inducing nitric oxide production in infected gamma interferon-activated macrophages. Infect Immun 63 (1995) 4862-4867
151. Munoz-Fernandez M.A., Fernandez M.A., and Fresno M. Synergism between tumor necrosis factor-alpha and interferon-gamma on macrophage activation for the killing of intracellular Trypanosoma cruzi through a nitric oxide-dependent mechanism. Eur J Immunol 22 (1992) 301-307
152. Vespa G.N., Cunha F.Q., and Silva J.S. Nitric oxide is involved in control of Trypanosoma cruzi-induced parasitemia and directly kills the parasite in vitro. Infect Immun 62 (1994) 5177-5182
153. Petray P., Castanos-Velez E., Grinstein S., et al. Role of nitric oxide in resistance and histopathology during experimental infection with Trypanosoma cruzi. Immunol Lett 47 (1995) 121-126
154. Chandrasekar B., Melby P.C., Troyer D.A., et al. Differential regulation of nitric oxide synthase isoforms in experimental acute Chagasic cardiomyopathy. Clin Exp Immunol 121 (2000) 112-119
155. Huang H., Chan J., Wittner M., et al. Expression of cardiac cytokines and inducible form of nitric oxide synthase (NOS2) in Trypanosoma cruzi-infected mice. J Mol Cell Cardiol 31 (1999) 75-88
156. Holscher C., Kohler G., Muller U., et al. Defective nitric oxide effector functions lead to extreme susceptibility of Trypanosoma cruzi-infected mice deficient in gamma interferon receptor or inducible nitric oxide synthase. Infect Immun 66 (1998) 1208-1215
157. Cummings K.L., and Tarleton R.L. Inducible nitric oxide synthase ss not essential for control of Trypanosoma cruzi infection in mice. Infect Immun 72 (2004) 4081-4089
158. Pinge-Filho P., Peron J.P.S., de Moura T.R., et al. Protective immunity against Trypanosoma cruzi provided by oral immunization with Phytomonas serpens: role of nitric oxide. Immunol Lett 96 (2005) 283-290
159. Gazzinelli R.T., Oswald I.P., Hieny S., et al. The microbicidal activity of interferon-[gamma]-treated macrophages against Trypanosoma cruzi involves an L-arginine-dependent, nitrogen oxide-mediated mechanism inhibitable by interleukin-10 and transforming growth factor-[beta]. Eur J Immunol 22 (1992) 2501-2506
160. Rodrigues M.M., Ribeirao M., and Boscardin S.B. CD4 Th1 but not Th2 clones efficiently activate macrophages to eliminate Trypanosoma cruzi through a nitric oxide dependent mechanism. Immunol Lett 73 (2000) 43-50
161. Villalta F., Zhang Y., Bibb K.E., et al. The cysteine-cysteine family of chemokines RANTES, MIP-1[alpha], and MIP-1[beta] induce trypanocidal activity in human macrophages via nitric oxide. Infect Immun 66 (1998) 4690-4695
162. Chandra M., Tanowitz H.B., Petkova S.B., et al. Significance of inducible nitric oxide synthase in acute myocarditis caused by Trypanosoma cruzi (Tulahuen strain). Int J Parasitol 32 (2002) 897-905
163. Perez-Fuentes R., Sanchez-Guillen M.C., Gonzalez-Alvarez C., et al. Humoral nitric oxide levels and antibody immune response of symptomatic and indeterminate Chagas' disease patients to commercial and autochthonous Trypanosoma cruzi antigen. Am J Trop Med Hyg 58 (1998) 715-720
164. Lauer B., Padberg K., Schultheiss H.P., et al. Autoantibodies against human ventricular myosin in sera of patients with acute and chronic myocarditis. J Am Coll Cardiol 23 (1994) 146-153
165. Schultheiss H.P., Schulze K., and Dorner A. Significance of the adenine nucleotide translocator in the pathogenesis of viral heart disease. Mol Cell Biochem 163-164 (1996) 319-327
166. Lauer B., Schannwell M., Kuhl U., et al. Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol 35 (2000) 11-18
167. Ishiyama S., Hiroe M., Nishikawa T., et al. Inhibitory effects of vesnarinone in the progression of myocardial damage in experimental autoimmune myocarditis in rats. Cardiovasc Res 43 (1999) 389-397
168. Goren N., Leiros C.P., Sterin-Borda L., et al. Nitric oxide synthase in experimental autoimmune myocarditis dysfunction. J Mol Cell Cardiol 30 (1998) 2467-2474
169. Shin T., Tanuma N., Kim S., et al. An inhibitor of inducible nitric oxide synthase ameliorates experimental autoimmune myocarditis in Lewis rats. J Neuroimmunol 92 (1998) 133-138
170. Ishiyama S., Hiroe M., Nishikawa T., et al. Nitric oxide contributes to the progression of myocardial damage in experimental autoimmune myocarditis in rats. Circulation 95 (1997) 489-496
171. Hirono S., Islam M.O., Nakazawa M., et al. Expression of inducible nitric oxide synthase in rat experimental autoimmune myocarditis with special reference to changes in cardiac hemodynamics. Circ Res 80 (1997) 11-20
172. Eriksson U., Kurrer M.O., Bingisser R., et al. Lethal autoimmune myocarditis in interferon-{{gamma}} receptor-deficient mice: enhanced disease severity by impaired inducible nitric oxide synthase induction. Circulation 103 (2001) 18-21
173. Bachmaier K., Neu N., Pummerer C., et al. iNOS expression and nitrotyrosine formation in the myocardium in response to inflammation is controlled by the interferon regulatory transcription factor 1. Circulation 96 (1997) 585-591
174. Yuan Z., Kishimoto C., and Shioji K. Beneficial effects of low-dose benidipine in acute autoimmune myocarditis: suppressive effects on inflammatory cytokines and inducible nitric oxide synthase. Circ J 67 (2003) 545-550
175. Olivetti G., Abbi R., Quaini F., et al. Apoptosis in the failing human heart. N Engl J Med 336 (1997) 1131-1141
176. Narula J., Haider N., Virmani R., et al. Apoptosis in myocytes in end-stage heart failure. N Engl J Med 335 (1996) 1182-1189
177. Seko Y., Kayagaki N., Seino K., et al. Role of Fas/FasL pathway in the activation of infiltrating cells in murine acute myocarditis caused by Coxsackievirus B3*1. J Am Coll Cardiol 39 (2002) 1399-1403
178. Dimmeler S., Haendeler J., Nehls M., et al. Suppression of apoptosis by nitric oxide via inhibition of interleukin-1beta -converting enzyme (ICE)-like and cysteine protease protein (CPP)-32-like Proteases. J Exp Med 185 (1997) 601-608
179. Li J., Billiar T.R., Talanian R.V., et al. Nitric oxide reversibly inhibits seven members of the caspase family via S-nitrosylation. Biochem Biophys Res Commun 240 (1997) 419-424
180. Mohr S., Zech B., Lapetina E.G., et al. Inhibition of caspase-3 by S-nitrosation and oxidation caused by nitric oxide. Biochem Biophys Res Commun 238 (1997) 387-391
181. Mannick J.B., Hausladen A., Liu L., et al. Fas-induced caspase denitrosylation. Science 284 (1999) 651-654
182. Shimojo T., Hiroe M., Ishiyama S., et al. Nitric oxide induces apoptotic death of cardiomyocytes via a cyclic-GMP-dependent pathway. Exp Cell Res 247 (1999) 38-47